Visus Therapeutics announced today that it entered into worldwide licensing agreements with Cella Therapeutics and DelSiTech. The exclusive worldwide licensing agreement with Cella covers the development of investigational ophthalmic therapies for treating glaucoma and age-related macular degeneration (AMD). The additional worldwide exclusive licensing agreement with DelSiTech will lead to the development of novel drug delivery […]
Business/Financial News
NovaBay Pharmaceuticals to distribute Okra Limited’s dry eye products
NovaBay Pharmaceuticals (NYSE:NBY) announced today that it agreed with Okra Limited to distribute its Zocular dry eye products. The agreement allows NovaBay to distribute Zocular dry eye products alongside Avenova in its physician-dispensed sales channel. Zocular products are formulated with patented Zokrex technology, which contains activated natural okra polysaccharide complexes designed to gently and effectively […]
Ultrahuman raises $17.5M Series B for wearable glucose monitoring tech
Ultrahuman announced today that it raised $17.5 million in a Series B financing round for its wearable glucose tracking technology. Bangalore, India-based Ultrahuman develops the Ultrahuman Cyborg, a continuous metabolism tracker designed to help people with diabetes track blood glucose in real-time and optimize their diet and exercise. The platform goes beyond traditional markers like […]
Stevanato Group brings in upsized IPO worth $453.5M
Stevanato Group announced today that the underwriters of its recently completed initial public offering purchased more than 1 million additional shares. The option exercised by the underwriters saw the acquisition of an additional 1,018,280 ordinary Stevanato Group shares at $21 per share. Piombino Dese, Italy–based Stevanato Group’s IPO resulted in net proceeds of approximately $453.5 […]
Eli Lilly forms neuroscience and immunology units amid leadership changes
Eli Lilly (NYSE:LLY) today announced executive leadership changes as it creates neuroscience and immunology business units. Indianapolis-based Eli Lilly split its bio-medicines segment into Lilly Neuroscience and Lilly Immunology in the organizational shift, to be made effective Sept. 5, with Anne White set to lead the neuroscience unit and Patrik Jonsson set to head up […]
Sinomed launches HT Supreme drug-eluting stent in Europe
Sinomed has completed the first commercial implantation of its HT Supreme drug-eluting stent in Ireland. Faisal Sharif, professor of translational cardiovascular medicine and innovation at the National University of Ireland Galway, successfully performed the first procedure with HT Supreme, a healing-targeted drug-eluting stent designed to treat patients with narrowing or blockages to their coronary arteries. […]
Xeris reaches payor coverage milestone for glucagon injection
Xeris Pharmaceuticals (NSDQ:XERS) announced today that it achieved a milestone for the payor coverage of its Gvoke glucagon injection. Approximately 91% of Medicare patients, 88% of commercially insured patients and a growing number of Medicaid lives have unrestricted access to Gvoke, Xeris said in a news release. Chicago-based Xeris’ Gvoke, a ready-to-use pre-mixed, pre-measured glucagon […]
Bexson Biomedical aims to extend its wearable drug delivery device to psychoactive drugs
Bexson Biomedical announced today that it launched an R&D initiative to develop subcutaneous formulations of psychoactive therapeutics. Santa Barbara, Calif.-based Bexson’s effort will apply its existing subcutaneous formulation technology to build several psychoactive drug scaffolds for treating mental health indications, including post-traumatic stress disorder (PTSD) and depression. Formulations developed through the R&D initiative are designed […]
Senseonics slides on earnings miss in Q2
Senseonics (NYSE:SENS) shares took a hit today on second-quarter results that missed the consensus earnings forecast. The Germantown, Md.-based diabetes management technology developer posted losses of –$180.3 million on sales of $3.3 million for the three months ended June 30, 2021, seeing its bottom line plummet from losses of just –$7.5 million this time last […]
Ocular Therapeutix misses on earnings, tops Q2 revenue estimates
Ocular Therapeutix (NSDQ:OCUL) shares ticked up this morning on second-quarter results that topped revenue forecasts. OCUL shares were up nearly 2% at $10.94 apiece in morning trading today. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was down slightly. The Bedford, Mass.-based ophthalmology drug delivery company posted losses of […]